SANTA BARBARA, Calif.
, Feb. 3, 2020
/PRNewswire-PRWeb/ -- Palette Life Sciences, Inc., today announces the launch of MySolesta.com, an online educational resource specifically designed for healthcare professionals (HCPs), caregivers, and patients suffering from bowel incontinence, also known as fecal incontinence (FI). The site provides valuable information, education and resources focused on the causes, risk factors, symptoms and treatment options for FI, including Solesta® - the quick, nonsurgical treatment for bowel incontinence.(1)
MySolesta.com empowers patients and caregivers by providing them valuable information and connects them with physicians in their area who specialize in treating bowel incontinence. In addition, the site includes information and resources pertaining to reimbursement assistance for treatments.
Bowel incontinence or fecal incontinence affects millions of people worldwide. Research indicates that up to 18% of the general population worldwide suffers from bowel incontinence.(2) However, due to the shame and emotional toll of this condition, many people avoid seeking bowel incontinence treatment so the number of cases is likely higher.(3)
Bowel incontinence can present as anal leakage of loose stool, solid stool or mucus. Such uncontrollable anal discharge, can be upsetting, embarrassing, and may discourage patients to talk with their doctor about their bowel incontinence challenges.
For physicians, the site provides simple and straightforward information on training and certification for administering Solesta; HCPs can simply follow three easy steps at MySolesta.com.
Solesta is the only FDA-approved minimally invasive treatment for bowel incontinence. It is an easily injectable, viscous gel made from two polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA™) and Dextranomer (Dx) microspheres. The Solesta implant is stable, remains in position, and does not disappear over time.(3,4) Solesta is the only injectable gel to be administered in an outpatient setting without the need for anesthesia.(1) Studies have shown that Solesta can help patients return to a more active lifestyle (socializing, going to work, etc.) and reduce overall depression and embarrassment associated with their bowel control problems.(5)
"For patients looking for a quick, nonsurgical fecal incontinence treatment, Solesta may be an ideal choice," said Dr. Zuri Murell
, Los Angeles
based colorectal surgeon and specialist. "My patients who opted for Solesta were pleased with the results. With the launch of the new MySolesta.com website, I hope patients find comfort knowing there is an effective treatment for their condition that can improve their quality of life and that they are not alone."
"We are confident that MySolesta.com will greatly help patients affected by bowel incontinence, as well as caregivers and the healthcare professionals treating this condition by providing them with valuable information and connecting patients and HCPs," said Richard Low
, Head of Marketing, Palette Life Sciences.
About Solesta Solesta, a Non-Animal Stabilized Hyaluronic Acid (NASHA™) and dextranomer gel, is a tissue bulking agent that is injected into the submucosal layer of the anal canal for treatment of Bowel Incontinence in adults. It's a minimally invasive, outpatient procedure that has been proven effective for up to 36 months. Learn more at MySolesta.com.
About Palette Life Sciences Palette Life Sciences is focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Palette Life Sciences, Inc. is a wholly owned subsidiary of Pharmanest AB headquartered in Stockholm, Sweden
. Learn more at MySolesta.com and palettelifesciences.com.
1. Solesta [Package Insert]. Santa Barbara, CA
: Palette Life Sciences. 2. Ng K, Sivakumaran Y, Nassar N, Gladman MA. Fecal incontinence: community prevalence and associated factors–a systematic review. Dis Colon Rectum. 2015;58(12):1194-1209. 3. Irwin T, Snow AR, Orton TS, Elliot C. Endoscopic, ultrasonographic, and histologic descriptions of dextranomer/hyaluronic acid in a case of fecal incontinence. Case Reports in Pathology. 2018. 4. Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children. Adv Urol. 2008;513854. 5. Graf W, Mellgren KE, et al; for NASHA Dx study group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, shame-controlled trial. Lancet. 2011;377(9770):977-1003.
SOURCE Palette Life Sciences